# Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

> **NCT00423007** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 90 (—)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Bromfenac
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00423007
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 90 (—)
- **Last updated:** 2013-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423007, "Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00423007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*